Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia - Trial NCT06344572
Access comprehensive clinical trial information for NCT06344572 through Pure Global AI's free database. This Phase 3 trial is sponsored by S-Alpha Therapeutics, Inc. and is currently Recruiting. The study focuses on Myopia. Target enrollment is 110 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
S-Alpha Therapeutics, Inc.
Timeline & Enrollment
Phase 3
Sep 27, 2023
Sep 30, 2025
Primary Outcome
Change in Cycloplegic Spherical Equivalent Refractive Error
Summary
The objective of this clinical investigation is to evaluate the efficacy and safety of
 SAT-001 designed as Software as Medical Device (SaMD) for slowing myopia progression and
 treatment in pediatric myopia patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06344572
Device Trial